Subscribe To
Replimune presents rp1 data from the ignyte anti-pd1 failed melanoma cohort and rp2 data in uveal melanoma at the 2023 american society of clinical oncology (asco) annual meeting
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab cont...
June 3, 2023, 6:15 pm
Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with n...
November 11, 2022, 5:00 pm
Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with n...
November 11, 2022, 5:00 pm
Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with n...
November 11, 2022, 5:00 pm
Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with n...
November 11, 2022, 5:00 pm
Bristol myers, nektar melanoma doublet therapy trial fails to show clinical benefit
Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 ...
March 14, 2022, 11:25 am
Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...
February 15, 2022, 9:14 am
Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...
February 15, 2022, 9:14 am
Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...
February 15, 2022, 9:14 am